Previous studies have shown that inhibition of cathepsin K attenuates obesity-induced increase in serum glucose and insulin, and improves systemic glucose utilization6, 11, 12, which is confirmed by our current study wherein cathepsin K knockout mice had lower serum glucose levels compared to the wildtype mice following STZ injection. Here, CTSK is linked to obesity disorder.